Amgen (AMGN) Tops Q4 EPS by 10c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amgen (AMGN) PT Raised to $202 at BMO Capital Amid Positive Repatha Data
February 3, 2017 6:53 AM ESTBMO Capital raised its price target on Amgen (NASDAQ: AMGN) to $202.00 (from $197.00) while maintaining a Outperform rating following positive Repatha CV outcomes data
Analyst M. Ian Somaiya commented, "Addition of CV outcomes data to the Repatha label and launch of erenumab for migraine... More
